Literature DB >> 19813249

High incidence of hearing loss in long-term survivors of multisystem Langerhans cell histiocytosis.

Vasanta Nanduri1, Ruth Tatevossian, Tony Sirimanna.   

Abstract

BACKGROUND: Ear involvement in the acute phase of Langerhans cell histiocytosis (LCH) is commonly seen and well documented, but the long-term sequelae are less well described, particularly in relation to hearing loss.
METHODS: We investigated 40 patients with biopsy-proven multisystem LCH >5 years from the end of treatment, using detailed audiological assessment and CT/MRI imaging of the petrous temporal bones.
RESULTS: The incidence of ear involvement in the acute phase of disease was 70%. Fifteen of the 39 patients tested (38%) had residual permanent hearing loss at long-term follow-up.
CONCLUSIONS: The incidence of hearing loss is much higher than has previously been reported in LCH, and may reflect a referral bias of young (<2 years) and more complex patients to our tertiary centre. However, the hearing loss appears to be highly specific to this patient group when compared to other long-term survivors of childhood cancers, probably due to the propensity of LCH to involve the ears. We therefore recommend audiology testing as an important part of long-term follow-up for patients with multisystem LCH. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 19813249     DOI: 10.1002/pbc.22186

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  Case report: Langerhans cell histiocytosis of the temporal bone in children: Challenging diagnosis of a rare disease with some pitfalls.

Authors:  Anja Pähler Vor der Holte; Hans-Jürgen Welkoborsky
Journal:  Clin Case Rep       Date:  2022-10-12

2.  Langerhans Cell Histiocytosis: A Diagnostic Challenge in the Oral Cavity.

Authors:  Mehmet Ali Altay; Alper Sindel; Öznur Özalp; Burak Kocabalkan; İrem Hicran Özbudak; Ramazan Erdem; Ozan Salim; Dale A Baur
Journal:  Case Rep Pathol       Date:  2017-10-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.